Contezolid tablet (MRX-I tablets) is successfully renewed for inclusion in the National Reimbursement Drug List (NRDL) at the original price in China.
MRX-8 Phase 1 clinical trial completed in China
MRX-5 Phase 1 clinical trial completed in Australia
MRX-4 for projection Phase 3 clinical trial completed in China

Contezolid tablet (MRX-I tablet) is added to the most recent National Reimbursement Drug List (NRDL) in China.
Successfully listed on the Science and Technology Innovation Board

China National Medical Products Administration (NMPA) approves Contezolid tablet (MRX-I tablet), for treatment of Complicated Skin and Soft Structure Infection

NDA of MRX-I tablets accepted and priority review granted by the National Medical Products Administration (NMPA)
MRX-8 IND approved in the US
Series D and E Financing

MRX-I Phase 3 clinical trial completed and New Drug Application (NDA) submitted in China
MRX-4 Phase 2 clinical trial in the US

Qualified Infectious Disease Product (QIDP) and Fast Track granted for MRX-I and MRX-4 in the US
MRX-4 IND approved in China

MRX-4 Phase 1 clinical trial completed in the US

MRX-I Phase 2 clinical trial completed in the US
Series C financing
MRX-1 Phase III clinical trial initiated in China

MRX-I Phase 2 clinical trial completed in China
Patents for MRX-4 and MRX-8 filed

MRX-1 Phase 1 clinical trial completed in Australia

Series B financing
MRX-I supplementary application approved in China

MRX-I supplementary application submitted in China

MRX-1 Phase 1 clinical trial completed in China

MRX-I IND approved in China

MRX-I investigation new drug (IND) application submitted in China

First drug candidate MRX-I discovered, patent filed

MicuRx founded in Shanghai and California
Series A financing